BI and Lilly extend Jardiance's application in heart failure
March 08, 2018 Source: Sina Pharmaceutical
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Recently, Boehringer Ingelheim (BI) and Lilly said that they are expanding their clinical trials for drug Jardiaance (empagliflozin) to treat chronic heart failure (CHF). Two new plans are planned. Phase III study.
The Emperial Clinical Trial Program will assess the efficacy of Jardiance in the exercise and heart failure symptoms of patients with chronic heart failure after 12 weeks of treatment with the drug, regardless of whether they have type 2 diabetes.
The initiative, which was launched last year after the EMPEROR trial, focused on long-term morbidity and mortality outcomes in patients with heart failure, as well as data from the landmark EMPA-REG OUTCOME trial, which showed the drug Reducing cardiovascular death in adults with type 2 diabetes and establishing cardiovascular disease was not associated with glycemic control at the start of the study.
Related experimental data show that when Jardiance is added to common first- and second-line diabetes drugs (such as metformin or sulfonylureas), cardiovascular mortality also declines.
Thomas Seck, vice president of clinical development and medical affairs at BI Primary Care, noted, "We are encouraged by the results of Jardiance's efficacy in heart failure found in the EMPA-REG OUTCOME trial and look forward to more positive data from other ongoing trials. â€
Heart failure affects 26 million people worldwide, and patients often have high morbidity and mortality. Jeff Emmick, vice president of diabetes product development at Lilly, said, "The symptoms of heart failure can have a profound impact on a patient's quality of life. More than three-quarters of heart failure patients find it difficult to perform routine activities. Currently, the market can help improve chronic conditions. Daily life treatment options for patients with heart failure are quite limited. We look forward to seeing Jardiance help solve this unmet clinical need."
Engliflozin is an oral, once-a-day, highly selective sodium-glucose co-transporter 2 (SGLT2) inhibitor approved for use in adult type 2 diabetes in Europe, the United States, and other markets worldwide. Engliflozin helps patients with type 2 diabetes with hyperglycemia to excrete excess sugar in the urine by inhibiting SGLT2. In addition, the use of the drug increases the excretion of sodium from the body and reduces the fluid load of the body's vascular system (ie, the volume of blood vessels). Diabetes, urinary sodium excretion, and osmotic diuresis that occur after the use of ngliflozin can help patients improve their cardiovascular outcomes.
In August 2014, the new drug for diabetes, ngreidex, was approved by the FDA to combine dietary and exercise for the treatment of adult patients with type 2 diabetes to improve glycemic control. Engliflin is not suitable for patients with type 1 diabetes, nor for patients with diabetic ketoacidosis (increased ketone body in blood or urine). Engleet is the third diabetes product approved by the Boehringer Ingelheim-Lilly Diabetes Alliance in the United States. The two previous SGLT2 drugs were dapagliflozin (Farxiga) approved in January 2014 and canagliflozin approved in March 2013. (Invokana). (Sina Pharmaceutical Compilation / Fan Dongdong)
Article reference source: BI, Lilly expand Jardiance programme in heart failure
Antimicrobial Central Venous Catheter
Central Venous Catheter,CVC,central venous catheter set,central venous catheter double lumen,central venous catheter kit
Anesthesia Medical Co., Ltd. , https://www.jssinoanesthesias.com